| ²é¿´: 2838 | »Ø¸´: 7 | |||
starlogoÒø³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóscienceͶ¸åµÄcover letterÄ£°å
|
|
¸Ð¾õÒªÇóµÄÄÚÈÝºÜ¶à ²»ÖªµÀËÄÜ·ÖÏíÒ»¸öÄ£°å£¿ лл |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
¸öÈËÊÕ¼¯µÄһЩÌû×Ó |
» ²ÂÄãϲ»¶
ÊÛSCIÒ»ÇøT0PÎÄÕ£¬ÎÒ:8.O.55.1.O.5.4,¿ÆÄ¿È«,¿É+¼±
ÒѾÓÐ4È˻ظ´
ÊÛSCIÒ»ÇøT0PÎÄÕ£¬ÎÒ:8O.55.1.O.5.4,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ4È˻ظ´
2026Äê8ÔÂ25ÈÕ¹ú×ÔÈ»·Å°ñǰͻȻÊÕµ½ÁÐÈëÆÀÉóר¼ÒÓʼþ£¬ÓйØÏµÂð£¿
ÒѾÓÐ20È˻ظ´
½ñÌìÎñί»á¿ªÍêÁË£¬Ã÷Ìì³ö½á¹ûÂð
ÒѾÓÐ22È˻ظ´
ÔÚ¼á±ù»¹¸Ç×ű±º£µÄʱºò£¬ÎÒ¿´µ½ÁËŷŵÄ÷»¨¡£
ÒѾÓÐ9È˻ظ´
Ã÷ÌìÓ¦¸Ã¿É²éÁË£¡£¿
ÒѾÓÐ6È˻ظ´
ÓÐûÓдóÉñ°ïÎÒ¿´¿´»ù½ð´úÂë
ÒѾÓÐ10È˻ظ´
·Å°ñǰµÄ²»µ¶¨
ÒѾÓÐ19È˻ظ´
ijЩ»ú¹¹£¬ÒÔЧÂʵÍΪÈÙ£¬ÒÔЧÂʵÍ×÷Ϊ´æÔÚ¸Ð
ÒѾÓÐ10È˻ظ´
2026¹ú×ÔÈ»º¯ÆÀ·Ñµ½ÕË
ÒѾÓÐ23È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ËÄǶùÓÐcover letter µÄÄ£°å£¿£¿
ÒѾÓÐ5È˻ظ´
Analytical SciencesͶ¸åÇóÖú
ÒѾÓÐ15È˻ظ´
COVER LETTER£¨Í¶¸åÐÅ£©ÊµÓÃÖ¸ÄÏ
ÒѾÓÐ42È˻ظ´
¼±ÇóJPCC Ͷ¸åµÄcover letterÄ£°å~~
ÒѾÓÐ5È˻ظ´
tsingtao84
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 3.7
- É¢½ð: 46
- Ìû×Ó: 171
- ÔÚÏß: 48.2Сʱ
- ³æºÅ: 269800
- ×¢²á: 2006-08-05
- רҵ: ºÏ³ÉÒ©Îﻯѧ
2Â¥2011-09-23 23:16:03
|
±¾ÌûÄÚÈݱ»ÆÁ±Î |
3Â¥2011-09-23 23:23:09
starlogo
Òø³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 281.1
- É¢½ð: 60
- Ìû×Ó: 368
- ÔÚÏß: 48.9Сʱ
- ³æºÅ: 100857
- ×¢²á: 2005-11-12
- ÐÔ±ð: GG
- רҵ: ×ÊÔ´»·¾³Õþ²ßÓë¹ÜÀí
4Â¥2011-09-26 09:35:38
starlogo
Òø³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 281.1
- É¢½ð: 60
- Ìû×Ó: 368
- ÔÚÏß: 48.9Сʱ
- ³æºÅ: 100857
- ×¢²á: 2005-11-12
- ÐÔ±ð: GG
- רҵ: ×ÊÔ´»·¾³Õþ²ßÓë¹ÜÀí
5Â¥2011-09-28 22:50:42
sd116202
ľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 11 (СѧÉú)
- ½ð±Ò: 441.7
- É¢½ð: 706
- ºì»¨: 8
- Ìû×Ó: 1751
- ÔÚÏß: 236Сʱ
- ³æºÅ: 1111478
- ×¢²á: 2010-09-30
- ÐÔ±ð: GG
- רҵ: ¹¤³ÌÈÈÎïÀíÏà¹Ø½»²æÁìÓò
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
starlogo(½ð±Ò+10): 2011-09-29 21:46:32
|
Dear , I would like to submit the manuscript entitled, ¡°Key interactions of the mutant HIV-1 Reverse Transcriptase/Efavirenz: An evidence obtained from ONIOM method¡± to be published in MedChemComm. The main objective of this work is to find out the key residues in the binding site of the HIV-1 reverse transcriptase, bound with its inhibitor, based on the ONIOM method. This method has been applied to large biological system, but, still focused on the drug-enzyme interaction, calculated at high level of calculations. The obtained results indicate structural and energetic properties of the key residues (L101 and S105) which are important for the design of novel inhibitor, against mutant enzyme. This manuscript may be interesting to MedChemComm readers. It would be very kind, if you could consider this manuscript to be published in MedChemComm. I certify that this manuscript, or any part of it, has not been published and will not be submitted elsewhere for publication while being considered by the journal MedChemComm. May I ask for your kind consideration for this purpose? I am very appreciated by your kindness. Looking forward to hearing from you. Sincerely yours, |
6Â¥2011-09-29 08:24:37
Ã÷³¯ÄÇЩʶù
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1015.9
- É¢½ð: 244
- ºì»¨: 3
- Ìû×Ó: 533
- ÔÚÏß: 193.7Сʱ
- ³æºÅ: 878494
- ×¢²á: 2009-10-20
- רҵ: µç»¯Ñ§

7Â¥2011-09-29 08:24:43
njuststeven
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1446.6
- É¢½ð: 8
- Ìû×Ó: 454
- ÔÚÏß: 109.1Сʱ
- ³æºÅ: 446788
- ×¢²á: 2007-10-30
- ÐÔ±ð: GG
- רҵ: ¾ÛºÏÎï¹²»ìÓ븴ºÏ²ÄÁÏ
8Â¥2013-10-12 21:09:58









»Ø¸´´ËÂ¥
science
28